CA2835438A1 - Pirfenidone and anti-fibrotic therapy in selected patients - Google Patents

Pirfenidone and anti-fibrotic therapy in selected patients Download PDF

Info

Publication number
CA2835438A1
CA2835438A1 CA2835438A CA2835438A CA2835438A1 CA 2835438 A1 CA2835438 A1 CA 2835438A1 CA 2835438 A CA2835438 A CA 2835438A CA 2835438 A CA2835438 A CA 2835438A CA 2835438 A1 CA2835438 A1 CA 2835438A1
Authority
CA
Canada
Prior art keywords
pirfenidone
receptor
inhibitor
agent
fvc
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2835438A
Other languages
English (en)
French (fr)
Inventor
Williamson Ziegler Bradford
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Intermune Inc
Original Assignee
Intermune Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Intermune Inc filed Critical Intermune Inc
Publication of CA2835438A1 publication Critical patent/CA2835438A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/217—IFN-gamma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA2835438A 2011-05-25 2012-05-25 Pirfenidone and anti-fibrotic therapy in selected patients Abandoned CA2835438A1 (en)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201161489936P 2011-05-25 2011-05-25
US61/489,936 2011-05-25
US201161490057P 2011-05-26 2011-05-26
US61/490,057 2011-05-26
US201161523047P 2011-08-12 2011-08-12
US61/523,047 2011-08-12
US201161524961P 2011-08-18 2011-08-18
US61/524,961 2011-08-18
PCT/US2012/039538 WO2012162592A1 (en) 2011-05-25 2012-05-25 Pirfenidone and anti-fibrotic therapy in selected patients

Publications (1)

Publication Number Publication Date
CA2835438A1 true CA2835438A1 (en) 2012-11-29

Family

ID=47217770

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2835438A Abandoned CA2835438A1 (en) 2011-05-25 2012-05-25 Pirfenidone and anti-fibrotic therapy in selected patients

Country Status (11)

Country Link
US (1) US20150164874A1 (cg-RX-API-DMAC7.html)
EP (1) EP2713732A4 (cg-RX-API-DMAC7.html)
JP (1) JP6170040B2 (cg-RX-API-DMAC7.html)
KR (1) KR20140022048A (cg-RX-API-DMAC7.html)
AU (1) AU2012258575B2 (cg-RX-API-DMAC7.html)
CA (1) CA2835438A1 (cg-RX-API-DMAC7.html)
HK (1) HK1197159A1 (cg-RX-API-DMAC7.html)
IL (1) IL229226A0 (cg-RX-API-DMAC7.html)
MX (1) MX2013013752A (cg-RX-API-DMAC7.html)
SG (1) SG195110A1 (cg-RX-API-DMAC7.html)
WO (1) WO2012162592A1 (cg-RX-API-DMAC7.html)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2008265595B2 (en) 2007-06-20 2014-12-04 PureTech LYT 100 Inc. Substituted N-Aryl pyridinones as fibrotic inhibitors
BR112013022766A2 (pt) * 2011-03-08 2016-12-06 Auspex Pharmaceuticals Inc método de administração de d-pirfenidona e kit
AR092742A1 (es) 2012-10-02 2015-04-29 Intermune Inc Piridinonas antifibroticas
CA3280124A1 (en) 2013-07-31 2025-10-31 Avalyn Pharma Inc. Aerosol imatinib compounds and uses thereof
RU2692485C2 (ru) 2014-04-02 2019-06-25 Интермьюн, Инк. Противофиброзные пиридиноны
EP3194446B1 (en) * 2014-09-18 2022-10-26 Cedars-Sinai Medical Center Compositions and methods for treating fibrosis
DK3050574T3 (da) * 2015-01-28 2020-01-20 Univ Bordeaux Anvendelse af plerixafor til behandling og/eller forebyggelse af akutte forværringer af kronisk obstruktiv lungesygdom
US20180064662A1 (en) * 2015-03-05 2018-03-08 The General Hospital Corporation Novel compositions and uses of metformin agents
SG11201907673YA (en) * 2017-03-13 2019-09-27 Genfit Pharmaceutical compositions for combination therapy
US20210363259A1 (en) * 2017-08-22 2021-11-25 Biogen Ma Inc. Pharmaceutical compositions and dosage regimens containing anti-alpha(v)beta(6) antibodies
CA3140129A1 (en) * 2019-05-17 2020-11-26 The Regents Of The University Of California Mps modified peptides and use thereof
CN112239507A (zh) 2019-07-17 2021-01-19 鸿运华宁(杭州)生物医药有限公司 ETA抗体与TGF-β Trap的融合蛋白质,以及其药物组合物和应用
EP3821946A1 (en) * 2019-11-12 2021-05-19 Université de Strasbourg Anti-claudin-1 monoclonal antibodies for the prevention and treatment of fibrotic diseases
WO2021110805A1 (en) 2019-12-04 2021-06-10 Idorsia Pharmaceuticals Ltd Combination of an azetidine lpa1 receptor antagonist with pirfenidone and/or nintedanib for use in the treatment of fibrotic diseases
US20230129866A1 (en) * 2020-03-13 2023-04-27 Puretech Lyt 100, Inc. Methods of treating respiratory disease with deupirfenidone
CN114617890A (zh) * 2020-12-08 2022-06-14 四川夏派森医药科技有限公司 DH404在治疗SARS-CoV-2感染中的应用
CN112640887B (zh) * 2020-12-25 2022-05-13 武汉睿健医药科技有限公司 一种神经干细胞冻存液及其应用
WO2022266370A1 (en) * 2021-06-17 2022-12-22 Aria Pharmaceuticals, Inc. Sparsentan for treating idiopathic pulmonary fibrosis
CN114097807B (zh) * 2021-11-25 2023-05-05 兰州大学 巴多索隆类化合物在抗农业病原真菌中的用途
WO2023192646A1 (en) * 2022-03-31 2023-10-05 Puretech Lyt 100, Inc. Methods of treating fibrotic- and collagen-mediated diseases and disorders with deupirfenidone

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE420878T1 (de) * 2000-02-18 2009-01-15 Kyowa Hakko Kirin Co Ltd Isoxazol- und thiazolverbindungen und ihre verwendung als medikamente
CN1307997C (zh) * 2002-06-28 2007-04-04 图兰恩教育基金管理人 用于治疗肺纤维化的4-(4-甲基哌嗪-1-基甲基)-n-[4-甲基-3-(4-(吡啶-3-基)嘧啶-2-基氨基)苯基]-苯甲酰胺
WO2004103296A2 (en) * 2003-05-16 2004-12-02 Intermune, Inc. Methods of treating idiopathic pulmonary fibrosis
WO2005110478A2 (en) * 2004-04-13 2005-11-24 Intermune, Inc. Combination therapy for treating fibrotic disorders
WO2007119214A2 (en) * 2006-04-13 2007-10-25 Actelion Pharmaceuticals Ltd Endothelin receptor antagonists for early stage idiopathic pulmonary fibrosis
HUE052220T2 (hu) * 2006-09-08 2021-04-28 Abbvie Bahamas Ltd Interleukin-13 kötõfehérjék
AU2008265595B2 (en) * 2007-06-20 2014-12-04 PureTech LYT 100 Inc. Substituted N-Aryl pyridinones as fibrotic inhibitors
EP2389227A4 (en) * 2009-01-26 2012-08-08 Intermune Inc METHOD FOR THE TREATMENT OF ACUTE MYOCARDINE CARDS AND ASSOCIATED ILLNESSES THEREOF
GB2474748B (en) * 2009-10-01 2011-10-12 Amira Pharmaceuticals Inc Polycyclic compounds as lysophosphatidic acid receptor antagonists

Also Published As

Publication number Publication date
NZ617415A (en) 2017-07-28
US20150164874A1 (en) 2015-06-18
EP2713732A1 (en) 2014-04-09
JP6170040B2 (ja) 2017-07-26
WO2012162592A1 (en) 2012-11-29
JP2014518880A (ja) 2014-08-07
KR20140022048A (ko) 2014-02-21
HK1197159A1 (en) 2015-01-09
SG195110A1 (en) 2013-12-30
EP2713732A4 (en) 2014-12-03
AU2012258575A1 (en) 2013-11-21
AU2012258575B2 (en) 2017-03-02
IL229226A0 (en) 2014-01-30
MX2013013752A (es) 2014-08-01

Similar Documents

Publication Publication Date Title
US20150164874A1 (en) Pirfenidone and anti-fibrotic therapy in selected patients
EP2285366B1 (fr) Molecules inhibant une voie metabolique impliquant la proteine tyrosine kinase syk et procede d'identification de ces molecules
US20240269126A1 (en) Combination therapy for treatment of cancer
CN115297862A (zh) 包含达拉菲尼、erk抑制剂和shp2抑制剂的三重药物组合
JP2021185144A (ja) 神経変性疾患と関連する幻覚の予防および処置のために有用な5−ht2aセロトニン受容体のモジュレーターとしてのジアリールおよびアリールヘテロアリール尿素誘導体
CN102908347A (zh) 取代的喹啉衍生物在治疗耐药性分枝杆菌性疾病中的用途
JP2014518880A5 (cg-RX-API-DMAC7.html)
JP2017504611A (ja) 組合せ医薬
US20220251105A1 (en) Methods of treating a mk2-mediated disorder
KR20180125966A (ko) 근위축성 측색 경화증 환자 아집단의 치료를 위한 마시티닙의 용도
JP2012515737A (ja) メトトレキサートおよびdhodh阻害剤を含む組合せ剤
TW201841637A (zh) 使用ccr3-抑制劑治療老化相關損傷之方法及組合物
JP2019525948A5 (cg-RX-API-DMAC7.html)
TW202615042A (zh) 用於治療進行性纖維化間質性肺病之新穎治療組合
JP2023531863A (ja) 肺の機械的損傷によって促進される肺線維症状態の治療で使用するためのニューロキニン(nk)-1受容体拮抗薬
WO2021016369A1 (en) Pimavanserin for trating schizophrenia or for treating psychosis secondary to neurodegenerative disorders or depressive disorder
JP2012526772A (ja) ホスホイノシチド3−キナーゼ阻害剤および抗糖尿病性化合物の組合せ剤
WO2019053595A1 (en) INHIBITORS OF PROTEIN KINASE C FOR THE TREATMENT OF CHOROIDAL MELLANOMA
US20210353648A1 (en) Grapiprant unit dosage forms
JP2026082828A (ja) レボケトコナゾールによる疾患の処置方法
JP2023512025A (ja) 肺動脈性肺高血圧症をロダトリスタットで処置するための投与量および方法
JP2007519646A (ja) 体重の持続的低減のための化合物
JP7565132B2 (ja) がんの治療又は予防用医薬
JP2023504115A (ja) 肺動脈性肺高血圧症の治療方法
KR20200067859A (ko) Ccr3-억제제를 사용한 소양증, 건조증, 및 관련 질환을 치료하기 위한 방법 및 조성물

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20170524

FZDE Discontinued

Effective date: 20191024